Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864888 | 1.00 | YAP1 (0.44) | YAP1F2PRSS1ACEMAPK1 | |
| SCHEMBL864889 | 1.00 | YAP1 (0.44) | YAP1F2PRSS1ACEMAPK1 | |
| SCHEMBL865252 | 0.88 | DPP4 (0.44) | YAP1MAPK1KMT2AHRH2HRH1 | |
| SCHEMBL865253 | 0.88 | DPP4 (0.44) | YAP1MAPK1KMT2AHRH2HRH1 | |
| SCHEMBL865251 | 0.88 | DPP4 (0.44) | YAP1MAPK1KMT2AHRH2HRH1 | |
| SCHEMBL864987 | 0.87 | YAP1 (0.57) | YAP1MAPK1KMT2AHRH2HRH1 | |
| SCHEMBL864986 | 0.87 | YAP1 (0.57) | YAP1MAPK1KMT2AHRH2HRH1 | |
| SCHEMBL865572 | 0.85 | YAP1 (0.57) | YAP1MAPK1ALDH1A1LMNA | |
| SCHEMBL865573 | 0.85 | YAP1 (0.57) | YAP1MAPK1ALDH1A1LMNA | |
| SCHEMBL865750 | 0.84 | YAP1 (0.45) | YAP1MAPK1KMT2AHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | YAP1 3922/4885F2 3677/4885PRSS1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.